Standard BioTools

Standard BioTools EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Standard BioTools (LAB) as of Sep 21, 2026 is -3.01. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.91 — a change of 230.97% (lower).

EV/FCF

-3.01

YoY

230.97%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Standard BioTools is 2026 -3.01 . EV/FCF (Enterprise Value to Free Cash Flow) of Standard BioTools was 2025 -0.91 . It decreases by 230.97% lower compared to the previous year.

The Standard BioTools EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-19.84 USD
Jan 1, 2019
-11.28 USD
Jan 1, 2020
-14.80 USD
Jan 1, 2021
-8.26 USD
Jan 1, 2022
-3.54 USD
Jan 1, 2023
-8.24 USD
Jan 1, 2024
-0.91 USD
Jan 1, 2025
-3.01 USD
The Standard BioTools EV/FCF history
YEAREV/FCFYoY
-3.01+230.97%
-0.91-88.95%
-8.24+132.71%
-3.54-57.13%
-8.26-44.22%
-14.80+31.16%
-11.28-43.13%
-19.84-9.34%
-21.89+70.68%
-12.82+9.62%
-11.70-31.26%
-17.02
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

EV/FCF (Enterprise Value to Free Cash Flow) of Standard BioTools is -3.01 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Standard BioTools changed from -0.91 to -3.01, representing a 230.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Standard BioTools with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Standard BioTools

All Key Metrics — Standard BioTools